Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Cellectis S.A. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 34 | 1 | 32 | −1 |
| Shares | 10.5M | 7.04K | 10.2M | −292.0K (−2.8%) |
| Value | $51.1M | $34.1K | $32.5M | −$18.5M (−36.3%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Cellectis S.A. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 16,269 | $51.6K | 0.00% |
| Lido Advisors, LLC | 10,094 | $32.0K | 0.00% |
| Barclays PLC | 224 | $710 | 0.00% |
| Larson Financial Group LLC | 75 | $238 | 0.00% |
Sold out (5)
Institutions that held Cellectis S.A. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Point72 Asset Management, L.P. | 27,314 | $132.2K |
| Bank of America Corp | 3,514 | $17.0K |
| Parallel Advisors, LLC | 1,479 | $7.16K |
| Signaturefd, LLC | 662 | $3.20K |
| SageView Advisory Group, LLC | 115 | $557 |
Not filed for Q1 2026 yet (1)
Institutions that held Cellectis S.A. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Global Retirement Partners, LLC | 7,038 | $34.1K |